Skip to main navigation Main navigation About Us Pipeline & Programs Clinical Trials Investors Careers News Releases Items per page 10 November 22, 2021 Summary Toggle Alpine Immune Sciences Announces Participation in Fireside Chat at the 4th Annual Evercore ISI HealthCONx Conference SEATTLE --(BUSINESS WIRE)--Nov. 22, 2021-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced the company will participate in a fireside chat at Read More November 10, 2021 Summary Toggle Alpine Immune Sciences Provides Corporate Update and Reports Third Quarter 2021 Financial Results - Recent private placement enables expansion and acceleration of development plans across the portfolio - - Plenary presentation for ALPN-303 at the American College of Rheumatology Convergence 2021 Annual Meeting highlighting best in class potential - SEATTLE --(BUSINESS WIRE)--Nov. Read More November 8, 2021 Summary Toggle Alpine Immune Sciences to Present ALPN-303 Data at American College of Rheumatology Convergence 2021 Annual Meeting - ALPN-303 demonstrates superior immunomodulatory activity and efficacy in preclinical models - - Phase 1 study to begin Q4 2021 - SEATTLE --(BUSINESS WIRE)--Nov. 8, 2021-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company, today announced a presentation in Read More September 15, 2021 Summary Toggle Alpine Immune Sciences Announces $91 Million Private Placement SEATTLE --(BUSINESS WIRE)--Sep. 15, 2021-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced it has entered into a definitive securities purchase Read More September 7, 2021 Summary Toggle Alpine Immune Sciences Announces Participation in September Investor Conferences SEATTLE --(BUSINESS WIRE)--Sep. 7, 2021-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced that members of its management team will present at the Read More August 10, 2021 Summary Toggle Alpine Immune Sciences Provides Corporate Update and Reports Second Quarter 2021 Financial Results - Conference call and webcast today at 4:30 p.m. ET - SEATTLE --(BUSINESS WIRE)--Aug. 10, 2021-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today provided a Read More August 4, 2021 Summary Toggle Alpine Immune Sciences to Report Second Quarter 2021 Financial Results and to Present at Upcoming Investor Conferences SEATTLE --(BUSINESS WIRE)--Aug. 4, 2021-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will release second quarter 2021 financial Read More June 30, 2021 Summary Toggle Alpine Immune Sciences to Collaborate with Merck on Immuno-Oncology Study to Evaluate ALPN-202 in Combination with KEYTRUDA® (pembrolizumab) - First Patient Dosed in NEON-2 Clinical Trial - SEATTLE --(BUSINESS WIRE)--Jun. 30, 2021-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, announced today a Read More June 24, 2021 Summary Toggle Alpine Immune Sciences Announces First Patient Dosed in Synergy, ALPN-101 Phase 2 Lupus Clinical Trial and $45 million in Development Milestones Achieved Under AbbVie Collaboration SEATTLE --(BUSINESS WIRE)--Jun. 24, 2021-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, announced today that the first patient has been dosed in Synergy, a Read More June 8, 2021 Summary Toggle Alpine Immune Sciences Set to Join Russell 3000® Index SEATTLE --(BUSINESS WIRE)--Jun. 8, 2021-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, announced today Alpine is set to join the broad-market Russell 3000® Read More Pagination Current page 1 Page 2 Page 3 Page 4 … Next page Next Last page Last Displaying 1 - 10 of 120 results Toolkit CONTACT 188 East Blaine Street Suite 200 Seattle, WA 98102 206-788-4545 SITEMAP About Us Pipelines & Programs Clinical Trials Investors Careers Contact Us Legal TWITTER @AlpineImmuneSci LATEST TWEETS Tweets by @AlpineImmuneSci © 2021 Alpine Immune Sciences. All Rights Reserved, Alpine Immune Sciences Inc.